**Introduction to Biochemical Pharmacology and Drug Discovery**

Gabriel Magoma

[82] Batshaw ML, Wachtel RC, Thomas GH, Starrett A, Brusilow SW. Arginine-respon‐ sive asymptomatic hyperammonemia in the premature infant. The Journal of pedia‐

[83] Walser M, Batshaw M, Sherwood G, Robinson B, Brusilow S. Nitrogen metabolism in neonatal citrullinaemia. Clinical science and molecular medicine. 1977 Aug;53(2):

[84] Brusilow SW, Valle DL, Batshaw M. New pathways of nitrogen excretion in inborn

[85] Summar M. Current strategies for the management of neonatal urea cycle disorders.

[86] Iyer R, Jenkinson CP, Vockley JG, Kern RM, Grody WW, Cederbaum S. The human arginases and arginase deficiency. Journal of inherited metabolic disease. 1998;21

[87] Coman D, Yaplito-Lee J, Boneh A. New indications and controversies in arginine

[88] Kobayashi K, Sinasac DS, Iijima M, Boright AP, Begum L, Lee JR, et al. The gene mu‐ tated in adult-onset type II citrullinaemia encodes a putative mitochondrial carrier

[89] Closs EI. Expression, regulation and function of carrier proteins for cationic amino acids. Current opinion in nephrology and hypertension. 2002 Jan;11(1):99-107.

therapy. Clinical nutrition (Edinburgh, Scotland). 2008 Aug;27(4):489-96.

[90] Smith CG, Vane JR. The discovery of captopril. Faseb J. 2003 May;17(8):788-9.

[91] Smith CG, Vane JR. The discovery of captopril: a reply. Faseb J. 2004 Jun;18(9):935.

[92] Angus DC, Linde-Zwirble WT, Tam SW, Ghali JK, Sabolinski ML, Villagra VG, et al. Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine

[94] Lipton SA, Choi YB, Pan ZH, Lei SZ, Chen HS, Sucher NJ, et al. A redox-based mech‐ anism for the neuroprotective and neurodestructive effects of nitric oxide and related

[95] Cheung HS, Cushman DW. Inhibition of homogeneous angiotensin-converting en‐ zyme of rabbit lung by synthetic venom peptides of Bothrops jararaca. Biochim Bio‐

[96] Shen TT, Bogdanov A, Jr., Bogdanova A, Poss K, Brady TJ, Weissleder R. Magnetical‐ ly labeled secretin retains receptor affinity to pancreas acinar cells. Bioconjugate

[97] Uekama K, Hirayama F, Irie T. Cyclodextrin Drug Carrier Systems. Chemical re‐

therapy for blacks with heart failure. Circulation. 2005 Dec 13;112(24):3745-53.

[93] Beckman JS. Ischaemic injury mediator. Nature. 1990 May 3;345(6270):27-8.

nitroso-compounds. Nature. 1993 Aug 12;364(6438):626-32.

phys Acta. 1973 Feb 15;293(2):451-63.

chemistry. 1996 May-Jun;7(3):311-6.

views. 1998 Jul 30;98(5):2045-76.

errors of urea synthesis. Lancet. 1979 Sep 1;2(8140):452-4.

The Journal of pediatrics. 2001 Jan;138(1 Suppl):S30-9.

protein. Nature genetics. 1999 Jun;22(2):159-63.

trics. 1984 Jul;105(1):86-91.

173-81.

474 Drug Discovery

Suppl 1:86-100.

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/52014
